DailyIQ
|
Sector:HealthcareAll sectors
Last updated 10 minutes ago

AMGN·Amgen Inc.

$.
+. (+.%)
After Hours
High
$341.39
Open
$339.52
Market Cap
182.03B
52W High
$391.29
Low
$335.99
P. Close
$336.10
P/E
23.34
52W Low
$267.83
Fwd P/E
14.31
Mean Target
$352.23
Technical Score (1D)
32
SELL
News Sentiment
58
BULLISH
Amgen is currently being directly compared to Novo Nordisk, with a focus on their respective leadership in GLP-1 drugs and the depth of their drug pipelines. This analysis is framed for investor decision-making, evaluating diversification strategies and overall positioning within the healthcare sector. Investors should watch how this competitive landscape evolves, particularly concerning advancements in obesity and diabetes treatments. Additionally, Amgen was recently featured in Zacks' daily stock research report, indicating ongoing analyst attention. While specific details of the Zacks analysis were not provided, its inclusion suggests continued scrutiny of Amgen's market standing. The comparison with Novo Nordisk highlights the critical importance of pipeline breadth and diversification in the pharmaceutical industry's current competitive environment.
Earnings Summary
Amgen Inc. is a global biotechnology company dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics across critical areas such as immunology, oncology, cardiovascular disease, bone health, and nephrology. Operating within the broader Healthcare sector, specifically the Drug Manufacturers - General industry, Amgen leverages a diverse portfolio of medicines and strategic collaborations to address serious illnesses and maintain a competitive edge. In its most recent reported quarters, Amgen demonstrated a mixed but generally positive earnings trend. For Q1 2026, the company reported an actual EPS of $5.15 against an estimate of $4.77, and revenue of $8.618 billion against an estimate of $8.571 billion, indicating a beat on both fronts. This followed a strong Q4 2025 where actual EPS was $5.29, exceeding the estimate of $4.83, and revenue reached $9.866 billion, surpassing the estimate of $9.662 billion. The preceding quarters of 2025 also showed actual EPS exceeding estimates, with Q3 2025 at $5.64 (vs $5.01 est.) and Q2 2025 at $6.02 (vs $5.28 est.). Revenue data is not consistently provided for earlier quarters, making a direct comparison difficult, but the trend suggests consistent EPS beats in the most recent periods. Historically, Amgen has shown a trajectory of growth, with recent quarters consistently beating analyst EPS expectations. The company has demonstrated a pattern of exceeding earnings estimates in its last four reported quarters, indicating a reliable performance against projections. While revenue estimates were not always available, the actual revenue figures in the most recent quarters have also trended upwards, supporting the positive earnings trend. Recent news highlights a significant leadership transition with the retirement of its CFO, Peter Griffith, and the appointment of Thomas Dittrich. While this signals a focus on succession planning, analysts maintain a positive outlook, with Piper Sandler reiterating an Overweight rating and a $427 price target, citing expected revenue growth from key products like Uplizna and Tepezza. Investors will be watching for the successful integration of the new CFO and continued sales momentum from its key drugs, as well as any impact from new safety warnings in Japan, to gauge future performance.

EPS

EstBeatMiss
$4.00$4.57$5.14$5.71$6.28Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.59 - -
Q1'26$4.77$5.15+8.0%
Q4'25$4.83$5.29+9.6%
Q3'25$5.01$5.64+12.5%
Q2'25$5.28$6.02+14.1%
Q1'25$4.26$4.90+15.0%

Revenue

EstBeatMiss
$7.9B$8.4B$9.0B$9.6B$10.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$9.6B - -
Q1'26$8.6B$8.6B+0.5%
Q4'25$9.7B$9.9B+2.1%
Q3'25 - $9.6B -
Q2'25 - $9.2B -
Q1'25 - $8.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AMGN Stock Snapshot

AMGN is currently trading at $336.47, giving Amgen Inc. a market cap of 182.03B and a P/E ratio of 23.3. Today's range spans $335.99–$341.39, with shares opening at $339.52 and moving up $0.37 (0.1%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 58/100.

Over the past year AMGN has traded between $267.83 and $391.29 - the current price is +25.6% off the 52-week low and -14.0% from the high. 44 analysts cover the stock with a Hold consensus and a mean 12-month target of $352.23 (range $200.00–$427.00), implying upside of +4.7%.

AMGN is showing a SELL signal (32/100) with neutral sentiment (58/100). Price: $336.47 (in the middle of its 52-week range within $267.83–$391.29). (P/E: 23.3) At 182.03B in Healthcare market cap, a bearish technical read accompanied by negative sentiment often marks the beginning of an earnings revision cycle downward - active managers trim before the revisions become consensus, compounding the selling pressure.

The current SELL phase for AMGN (32/100) at $336.47 (in the middle of its 52-week range) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 58/100 (neutral) confirms that news flow is not providing a counternarrative. At 182.03B in Healthcare capitalization, AMGN has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $267.83–$391.29 range.